Phase I trials: From traditional to newer approaches. Part I

Journal of Psychiatric Practice

Volumn 17, Issue 3, 2011, Pages 200-203

  Macaluso, Matthew ^a   Krams, Michael ^b   Preskorn, Sheldon H ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b JOHNSON AND JOHNSON   (United States)

Author keywords

drug development; novel molecular entities; phase I clinical trials

Indexed keywords

CENTRAL NERVOUS SYSTEM AGENTS;

ADVERSE DRUG REACTION; ARTICLE; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG DOSE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; METHODOLOGY; NORMAL HUMAN; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL (TOPIC);

BIOETHICAL ISSUES; BIOTRANSFORMATION; BLOOD-BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; DRUG DESIGN; DRUGS, INVESTIGATIONAL; ENDPOINT DETERMINATION; HUMANS; NONTHERAPEUTIC HUMAN EXPERIMENTATION; PHARMACOGENETICS; PSYCHOTROPIC DRUGS; RESEARCH DESIGN; TECHNOLOGY TRANSFER;

EID: 79958039542     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000398413.44244.f8     Document Type: Article

References (17)

1. Spilker B. Guide to clinical trials. Lippincott Williams & Wilkins; 1991.
2. Wong DF, Tauscher J, Gründer G. The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology 2009;34:187-203.
3. Gallo P, Chuang-Stein C, Dragalin V, et al. Executive summary of the PhRMA Working Group on adaptive designs in clinical drug development. J Biopharmaceutical Statistics 2006;16:275-83.
4. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010;9:203-14.
5. Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther 1997;61:275-91. (Pubitemid 27145429)
6. McConnell, EE. The maximum tolerated dose: The debate. J Am Coll Toxicol 1989; 8:1115-20.
7. Dragalin V. Terminology and classification of adaptive designs. Drug Info J 2006;40:425-35.
8. Crane M, Newman MC. What level of effect is a no observed effect? Environ Toxicol Chem 2000;19:516-19. (Pubitemid 30240874)
9. Arbuck SG. Workshop on phase I study design-Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996. Ann Oncol 1996;7:567-73. (Pubitemid 26285635)
10. Meinert CL, Tonascia S. Clinical trials: Design, conduct, and analysis. New York:: Oxford University Press; 1986:3.
11. Kraemer HC, Morgan GA, Leech NL, et al. Measures of clinical significance. J Am Acad Child Adolesc Psych 2003;42:1524-9. (Pubitemid 39585985)
12. Kaitin KI, Deconstructing the drug development process: The new face of innovation. Clin Pharmacol Ther 2010;87:356-61
13. Preskorn SH. Clinical pharmacology of SSRIs. Caddo, OK: Professional Communications; 1996.
14. Preskorn SH. CNS drug development: Part I: The early period of CNS drugs. 2010;16:334-39.
15. Panza F, Frisardi V, Imbimbo BP, et al. Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads. Expert Opin Biol Ther 2011;11:679-86.
16. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76. (Pubitemid 18039085)
17. Lepping P, Sambhi RS, Whittington R, et al. Clinical relevance of findings in trials of antipsychotics: Systematic review. Br J Psychiatry 2011;198:341-5.